The portable medical devices industry is a fast growing world. With the advent of various smart technology and wireless capabilities, this medical field has become one of the most intriguing with the promise of great potential for future healthcare.
Researchers at Lund University in Sweden have discovered how to stop the destructive process that leads to cardiovascular disease in diabetic laboratory animals. It is well known that high blood sugar levels significantly raise the risk of cardiovascular disease. It is unclear, however, why this happens.
Many women get too little sleep, despite considerable evidence showing the importance of sleep to overall health. Now a new UC San Francisco study has discovered another reason why inadequate sleep may be harmful, especially to women and their hearts.
People suffering from type 2 diabetes and cardiovascular disease (CVD) are at an increased risk of cognitive decline, according to a new study from Wake Forest Baptist Medical Center. Lead author Christina E. Hugenschmidt, Ph.D., said the results from the Diabetes Heart Study-Mind (DHS-Mind) suggest that CVD is playing a role in cognition problems before it is clinically apparent in patients.
Measuring blood flow in the brain may be an easy, noninvasive way to predict stroke or hemorrhage in children receiving cardiac or respiratory support through a machine called ECMO, according to a new study by researchers at Nationwide Children’s Hospital. Early detection would allow physicians to alter treatment and take steps to prevent these complications—the leading cause of death for patients on ECMO.
St. Jude Medical Initiates First US Clinical Study of the EnligHTN Renal Denervation System for Drug-Resistant High Blood PressureJune 4, 2013 8:00 am | by Business Wire | News | Comments
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval to begin the EnligHTN IV Renal Denervation Study, the first U.S. trial using the EnligHTN ™ Multi-Electrode Renal Denervation System to treat patients with drug-resistant high blood pressure.
The growth in sales of medical technologies is set to outperform prescription medicines over the coming five years. Data from Evaluate Medtech indicates that over the period 2011 to 2018, the overall global compound annual growth rate for the sector will be 4.4%, in contrast to just 2.5% for drug products.
Vasomedical to Raise Awareness about EECP@ Therapy as an Effective Treatment for Heart Disease in Diabetic PatientsJune 3, 2013 8:30 am | by The Associated Press | News | Comments
The American Heart Association (AHA) Heart Disease and Stroke 2013 Statistical Update reported that 19.7 million Americans over the age of twenty have physician-diagnosed diabetes, and there are an additional eight million Americans with undiagnosed diabetes. The top causes of disability and...
Continuing to demonstrate its ongoing commitment to advancing interventional treatments of peripheral artery disease and the evidence to support their adoption, Medtronic, Inc. announced today that enough patients have been enrolled in its clinical studies of the IN.PACT Admiral drug-eluting balloon to support the company's U.S. regulatory approval submission of the novel angioplasty device.
Invisalign, a San Jose company, uses 3-D printing to make each mouthful of customized, transparent braces. Mackenzies Chocolates, a confectioner in Santa Cruz, uses a 3-D printer to pump out chocolate molds. And earlier this year, Cornell University researchers used a 3-D printer, along with injections of a special collagen gel, to create a human-shaped ear.
One of the most interesting things about my position is seeing the changes in one of the most dynamic industries around—the medical device industry (and, in a broader sense, the healthcare industry). In my 13+ years of reporting on this industry, I’ve seen many changes and technological advances. It truly is remarkable to think about how far certain sectors of the industry have come in what is really a very short period of time.
The Endurant AAA stent graft system from Medtronic, Inc. continues to distinguish itself, with new data on the market-leading device for the endovascular repair of abdominal aortic aneurysms demonstrating durable clinical performance through three years of patient follow-up.
Stent angioplasty saves lives, but there often are side effects and complications related to the procedure, such as arterial restenosis and thrombosis. In the June 2013 issue of The FASEB Journal, however, scientists report that they have discovered a new nanoparticle gene delivery method that may overcome current limitations of gene therapy vectors and prevent complications associated with the stenting procedure.
Procedures like angioplasty, stenting and bypass surgery may save lives, but they also cause excessive inflammation and scarring, which ultimately can lead to permanent disability and even death. A new research report appearing in The FASEB Journal, shows that naturally derived compounds from polyunsaturated fatty acids (omega-3s) may reduce the inflammation associated with these procedures to help arteries more fully and completely heal.
A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health (BUSPH) and Boston Medical Center (BMC), the researchers differentiated induced pluripotent stem (iPS) cells into these cell types, which are typically obtained through blood donations.
Home healthcare and the use of medical devices outside of the professional healthcare environment are on the rise. Modern medicine allows us to live longer and provides those with chronic diseases the ability to receive medical care at home. Examples of home-use devices are oxygen concentrators, hospital beds, sleep apnea monitors, body-worn nerve and muscle stimulators, and dialysis machines, just to name a few.
Medtronic, Inc. (NYSE: MDT) is expanding its market-leading portfolio of products for endovascular aortic repair in the United States with two new medical devices: the company recently received approval from the U.S. Food and Drug Administration (FDA) for the Endurant II Aorto-Uni-Iliac (AUI) Stent Graft System and the FDA’s 510(k) clearance for the Sentrant Introducer Sheath.
Uscom (ASX: UCM) Uscom Limited today signed a deed to acquire all assets of Pulsecor Limited. Pulsecor Limited is a New Zealand company which has developed novel non-invasive central blood pressure measurement methods pioneered at the Weill Cornell Medical College in New York.
The technology at the heart of the next generation of medical devices is critical to our ability to offer comprehensive care in the coming decades. While our current systems of care have served us well thus far, they are crumbling under the pressures of modern expectations of care, economics, scale, and the sheer breadth of medical science.
Charlotte Based Compression And Vacuum Therapy Technology Helps Train Cyclist In Race Across AmericaMay 29, 2013 11:30 am | by PR Newswire | News | Comments
Austrian Cyclist Gerald Bauer will be directly benefiting from Charlotte based HYPOXI therapy and equipment to give him a possible racing edge in the Race Across America. Gerald will specifically use the Charlotte HYPOXI Multispectrum S120 device one week prior to the race and each day after the race. Dr. Fedor Fomin of HYPOXI will be providing the therapy.
Study of the Use of Control Catheters with the Sensei X Robotic System for the Treatment of Atrial FibrillationMay 29, 2013 8:00 am | by The Associated Press | News | Comments
Hansen Medical, Inc., a global leader in intravascular robotics, today announced that it has received conditional approval from the U.S. Food and Drug Administration to change the study design of its ARTISAN-AF Trial, a pivotal clinical trial evaluating the use of Hansen Medical's Artisan® family of Control Catheters with its Sensei® X Robotic Catheter System for treatment of Atrial Fibrillation, the most common cardiac arrhythmia.
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc., which Teleflex acquired in June 2012, completed CE marking requirements to market the company’s Arrow ® GPSCath ® Balloon Dilatation Catheters to the European Union.
The Food and Drug Administration said Thursday it approved a new blood test from Roche to help doctors diagnose diabetes. The Cobas Integra 800 is a blood test that measures a patient's average blood sugar level over the previous three months. In particular, the test measures an oxygen-carrying blood component known as hemoglobin.
New research is challenging medical guidelines that say people with a heart-zapping device in their chests should avoid intense sports like basketball and soccer in favor of golf or bowling. Lots of patients ignore that take-it-easy advice and stay in the game, and Monday's findings suggest vigorous exercise may be safe for many of them after all.
Aptus Endosystems, Inc. announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its 28mm Tip Reach Heli-FX™ Guide. A line extension of the original Heli-FX System, the new product enhances treatment of wide neck abdominal aortic aneurysms (AAA).